Poland’s Ryvu Therapeutics announces strategic reorganization

Ryvu Therapeutics (WSE: RVU) saw its shares tumble nearly 13% to 22.70 zloty by close of trading today, as the Polish oncology-focused biotech company announced a strategic reorganization that will extend Ryvu’s cash runway to second-half 2026 to focus on driving the RVU120 clinical program and the early pipeline to key data inflection points.

“We remain focused on advancing our first-in-class clinical blood cancer program RVU120, as well as promising early-stage assets. Considering our cash position, revenue projections, cost structure and the demanding market environment, we decided to optimize expenses so that the company has sufficient cash runway to generate key data for RVU120 and the preclinical pipeline, expecting that our achievements over the next year will support future cash inflows,” commented Ryvu’s chief executive Pawel Przewiezlikowski.

As of February 23, 2025 Ryvu held approximately 46 million euros ($48 million) (in cash and other financial assets. In addition, the company has secured approximately 22 million euros in non-dilutive grant funding.